...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Key Players

HI Bear,

The question I have pertaining to the Zen3694 trial is if they encountered Dose limiting toxicitity in any of the beginnging phases /cycle than I would think that the trial would have been stopped and a NR would been released. Since its not a double blinded trial the fact that we are near Cycle 4 of dosing and continuing the trial would be a good thing...... I am not scientist just a layman with all this science

Thanks

Share
New Message
Please login to post a reply